Harvard Bioscience is counting on huge returns from its Asia strategy where it plans to partner with Chinese companies and expand its distribution, says the scientific instrument-seller's CEO Jeff Duchemin. Duchemin says the company has gone through a major transformation after spinning off its regenerative technology unit last year, plus he says the harsh winter hampered sales in the first quarter. He says the company is now moving forward, especially in China, where he says the company is well positioned against traditional competitors like Thermo Fisher as well as smaller ones that continue to pop up.

More from Emerging Markets

Can You Trust the Q3 Data From China?

Can You Trust the Q3 Data From China?

Are We Looking at a Fourth Industrial Revolution? Jim Cramer Breaks It Down

Are We Looking at a Fourth Industrial Revolution? Jim Cramer Breaks It Down

Why These Countries Are Dumping U.S. Treasuries and What It Means for the Dollar

Why These Countries Are Dumping U.S. Treasuries and What It Means for the Dollar

The Next Opportunity May Be Overseas

The Next Opportunity May Be Overseas

3 Rail Stocks That Look Good on USMCA: Recon

3 Rail Stocks That Look Good on USMCA: Recon